JP2013526518A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526518A5
JP2013526518A5 JP2013510067A JP2013510067A JP2013526518A5 JP 2013526518 A5 JP2013526518 A5 JP 2013526518A5 JP 2013510067 A JP2013510067 A JP 2013510067A JP 2013510067 A JP2013510067 A JP 2013510067A JP 2013526518 A5 JP2013526518 A5 JP 2013526518A5
Authority
JP
Japan
Prior art keywords
item
nifedipine
pharmaceutical composition
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526518A (ja
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed filed Critical
Priority claimed from PCT/US2010/057287 external-priority patent/WO2011142778A1/en
Publication of JP2013526518A publication Critical patent/JP2013526518A/ja
Publication of JP2013526518A5 publication Critical patent/JP2013526518A5/ja
Pending legal-status Critical Current

Links

JP2013510067A 2010-05-13 2010-11-18 Mciおよびアルツハイマー病の処置 Pending JP2013526518A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
USPCT/US2010/034721 2010-05-13
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2013526518A JP2013526518A (ja) 2013-06-24
JP2013526518A5 true JP2013526518A5 (cg-RX-API-DMAC7.html) 2014-01-09

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510067A Pending JP2013526518A (ja) 2010-05-13 2010-11-18 Mciおよびアルツハイマー病の処置

Country Status (6)

Country Link
EP (1) EP2568811A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013526518A (cg-RX-API-DMAC7.html)
CN (1) CN102984938A (cg-RX-API-DMAC7.html)
AU (1) AU2010353287A1 (cg-RX-API-DMAC7.html)
CA (1) CA2799162A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011142778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
EP3015865B1 (en) 2013-06-28 2020-03-25 Mcbi Inc. Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
EA028587B1 (ru) * 2014-01-29 2017-12-29 Бристол-Майерс Сквибб Компани Ариллактамные ингибиторы киназы
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
EP3908307A4 (en) * 2019-01-07 2022-10-12 Cenna Biosciences Inc. NOVEL PEPTIDES AND USES THEREOF
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
EP1069918A4 (en) * 1998-04-08 2002-02-20 Univ Oregon Health Sciences ACTIVATION OF THE CELLULAR RECORDING OF THE GALLIUM
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
AU2001224250A1 (en) * 2000-11-21 2002-06-03 Howard Zik Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
AU2004292966A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
EP1955698B1 (en) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
MX2011003166A (es) * 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands

Similar Documents

Publication Publication Date Title
JP2013526518A (ja) Mciおよびアルツハイマー病の処置
JP2018502891A5 (cg-RX-API-DMAC7.html)
US9750747B2 (en) Treatments involving eslicarbazepine acetate or eslicarbazepine
AU2013334874B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
JP2012526844A (ja) Mciおよびアルツハイマー病の処置
JP2015510941A5 (cg-RX-API-DMAC7.html)
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
RU2005131845A (ru) Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера
JP2024525559A5 (cg-RX-API-DMAC7.html)
JP2021167361A (ja) 神経変性障害を処置するための方法
IL322574A (en) Compositions and methods for treating neurodegenerative diseases
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
JP2010531854A5 (cg-RX-API-DMAC7.html)
JP2020527172A5 (cg-RX-API-DMAC7.html)
CN120569199A (zh) 普利多匹定用于治疗青少年亨廷顿病
AU2021317186A1 (en) N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease
WO2025134069A1 (en) Compositions and methods for treating neurodegenerative disorders
JP2016047838A (ja) 酢酸エスリカルバゼピン及び使用方法
Ryan Agents I: Anti-infectives
Lovell et al. Treatment of MCI and Alzheimer's Disease
Iwatani et al. P-88 The effect of strong statins in diabetic nephropathy—comparison of atorvastatin and pitavastatin